Benzinga | Aug 25, 2021 04:45AM EDT

Morgan Stanley Downgrades Theravance Biopharma to Underweight, Lowers Price Target to $14

Morgan Stanley analyst Vikram Purohit downgrades Theravance Biopharma (NASDAQ:TBPH) from Overweight to Underweight and lowers the price target from $27 to $14.